Integrated and total HIV-1 DNA can predict quantitative viral outgrowth in patients on long-term ART

by W. De Spiegelaere, M. Kiselinova, M.J. Buzon, E. Malatinkova, M. Lichterfeld, L. Vandekerckhove
Published 2015-12-01

O2 Cross-validation of HIV DNA assays to quantify different HIV-1 subtypes by ddPCR

by S. Rutsaert, W. Trypsteen, C. Van Hecke, M.A. De Scheerder, M. Kiselinova, K. Vervisch, W. De Spiegelaere, L. Vandekerckhove
Published 2016-09-01

Integration site analysis of latently infected cell lines: evidence of ongoing replication

by J. Symons, S.R. Lewin, A. Chopra, E. Malantinkova, W. De Spiegelaere, S. Leary, D. Cooper, L. Vandekerckhove, S. Mallal, P. Cameron
Published 2015-12-01

Evaluation of the agreement between Brix refractometry and serum immunoglobulin concentration in neonatal piglets

by A. Schoos, W. De Spiegelaere, A. Cools, B. Pardon, E. Van Audenhove, E. Bernaerdt, G.P.J. Janssens, D. Maes
Published 2021-01-01

Impact of a decade of sustained antiretroviral therapy started during HIV-1 seroconversion on blood and gut reservoirs

by S. Kinloch, E. Malatinkova, W. De Spiegelaere, P. Bonczkowsk, M. Kiselinova, K. Vervisch, W. Trypsteen, M. Johnson, D. de Looze, L. Vandekerckhove
Published 2015-12-01

O5 The expression profile of host restriction factors in different cohorts of HIV-1-infected patients

by C. Van Hecke, E. Malatinkova, W. De Spiegelaere, M. Sips, K. Vervisch, C. Verhofstede, M. Johnson, S. Kinloch-de Loës, W. Trypsteen, L. Vandekerckhove
Published 2017-09-01

The CCR5-agonist maraviroc reverses HIV latency, results from ex vivo studies and a randomized placebo controlled clinical trial

by J. Symons, S.F.L. van Lelyveld, W. de Spiegelaere, A.M.J. Wensing, J. Drylewicz, A.I.M. Hoepelman, P.U. Cameron, H. Lu, T. Mota, A.I. Dantanarayana, L. Vandekerckhove, S.R. Lewin, K. Tesselaar, M. Nijhuis
Published 2017-12-01